Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 3/20 | 0.46 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048417 | 0.89 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3159765 | 0.86 | HRH3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14164269 | 0.84 | HDAC2 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL20176409 | 0.84 | HRH3 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2575502 | 0.83 | HRH3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4807896 | 0.82 | HDAC3 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4092990 | 0.82 | CRBN (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4818519 | 0.81 | HRH3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4608876 | 0.80 | HRH3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4813646 | 0.80 | HRH3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1755601-A2 | INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | disclosed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
| US-20050234033-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.